WO2005093044A1 - Mesenchymal stem cells and uses therefor - Google Patents

Mesenchymal stem cells and uses therefor Download PDF

Info

Publication number
WO2005093044A1
WO2005093044A1 PCT/US2005/008506 US2005008506W WO2005093044A1 WO 2005093044 A1 WO2005093044 A1 WO 2005093044A1 US 2005008506 W US2005008506 W US 2005008506W WO 2005093044 A1 WO2005093044 A1 WO 2005093044A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
cells
mesenchymal stem
stem cells
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/008506
Other languages
English (en)
French (fr)
Inventor
Mark F. Pittenger
Sudeepta Aggarwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osiris Therapeutics Inc
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39772836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005093044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP14172807.1A priority Critical patent/EP2824175B2/en
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Priority to ES05725577T priority patent/ES2385450T3/es
Priority to EP14172800.6A priority patent/EP2824174B1/en
Priority to JP2007505005A priority patent/JP2007530543A/ja
Priority to AT05725577T priority patent/ATE556134T1/de
Priority to AU2005227295A priority patent/AU2005227295A1/en
Priority to EP05725577A priority patent/EP1727892B1/en
Priority to CA2564679A priority patent/CA2564679C/en
Priority to EP18205743.0A priority patent/EP3461884B1/en
Publication of WO2005093044A1 publication Critical patent/WO2005093044A1/en
Anticipated expiration legal-status Critical
Priority to AU2009200019A priority patent/AU2009200019B2/en
Priority to AU2010200916A priority patent/AU2010200916A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0666—Mesenchymal stem cells from hair follicles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to mesenchymal stem cells. More particularly, this invention relates to novel uses for mesenchymal stem cells, including promoting angiogenesis in various tissues and organs, treating autoimmune diseases, treating allergic responses, treating cancer, treating inflammatory diseases and disorders, and promoting would healing.
  • MSCs Mesenchymal stem cells
  • MSCs may be useful in the repair or regeneration of damaged bone, cartilage, meniscus or myocardial tissues (DeKok, et al., Clin. Oral Implants Res.. Vol. 14, pg. 481 (2003)); Wu, et al., Transplantation, Vol. 75, pg. 679 (2003); Noel, et al., Curr. Qpin. Investig. Drugs, Vol. 3, pg. 1000 (2002); Ballas, et al., J. Cell. Biochem. Suppl., Vol. 38, pg.
  • MSCs express major histocompatibility complex (MHC) class I antigen on their surface but limited MHC class II (Le Blanc, et al., Exp. Hematol., Vol. 31 , pg. 890 (2003); Potian, et al., J. Immunol.. Vol. 171 , pg. 3426 (2003)) and no B7 or CD40 co- stimulatory molecules (Majumdar, et al., J. Biomed. Sci., Vol. 10, pg. 228 (2003)), suggesting that these cells have a low-immunogenic phenotype (Tse, et al., Transplantation. Vol. 75, pg. 389 (2003)).
  • MHC major histocompatibility complex
  • MSCs also inhibit T-cell proliferative responses in an MHC-independent manner (Bartholomew, et al., Exp. Hematol., Vol. 30, pg. 42 (2002); Devine, et al., Cancer J., Vol. 7, pg. 576 (2001 ); DiNicola, et al., Blood, Vol. 99, pg. 3838 (2002)).
  • These immunological properties of MSCs may enhance their transplant engraftment and limit the ability of the recipient immune system to recognize and reject allogeneic cells following transplantation.
  • MSCs mesenchymal stem cells with isolated immune cell populations, including dendritic cells (DC1 and DC2), effector T-cells (Th1 and Th2), and NK cells.
  • DC1 and DC2 dendritic cells
  • Th1 and Th2 effector T-cells
  • NK cells NK cells
  • mesenchymal stem cells may regulate the production of various factors that may regulate several steps in the immune response process.
  • the mesenchymal stem cells may be employed in the treatment of disease conditions and disorders involving the immune system, or diseases, conditions, or disorders involving inflammation or allergic responses.
  • diseases, conditions, and disorders include, but are not limited to, autoimmune diseases, allergies, arthritis, inflamed wounds, alopecia araeta (baldness), periodontal diseases including gingivitis and periodontitis, and other diseases, conditions or disorders involving an immune response.
  • PBMCs peripheral blood mononuclear cells
  • VEGF vascular endothelial growth factor
  • mesenchymal stem cells stimulate dendritic cells (DCs) to produce Interferon-Beta (IFN- ⁇ ), which promotes tumor suppression and immunity against viral infection.
  • DCs dendritic cells
  • IFN- ⁇ Interferon-Beta
  • a method of treating an autoimmune disease in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to treat the autoimmune disease in the animal.
  • IL-10 regulatory T-cells
  • DC dendritic cells
  • Autoimmune diseases which may be treated in accordance with the present invention include, but are not limited to, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, uveitis, autoimmune thyroid disease, inflammatory bowel disease, autoimmune lymphoproliferative disease (ALPS), demyelinating disease, autoimmune encephalomyelitis, autoimmune gastritis (AIG), and autoimmune glomerular diseases. It is to be understood, however, that the scope of the present invention is not to be limited to the treatment of the specific autoimmune diseases mentioned herein.
  • the animal to which the mesenchymal stem cells are administered is a mammal.
  • the mammal may be a primate, including human and non- human primates.
  • the mesenchymal stem cell (MSC) therapy is based, for example, on the following sequence: harvest of MSC-containing tissue, isolation and expansion of MSCs, and administration of the MSCs to the animal, with or without biochemical or genetic manipulation.
  • the mesenchymal stem cells that are administered may be a homogeneous composition or may be a mixed cell population enriched in MSCs.
  • Homogeneous mesenchymal stem cell compositions may be obtained by culturing adherent marrow or periosteal cells, and the mesenchymal stem cell compositions may be obtained by culturing adherent marrow or periosteal cells, and the mesenchymal stem cells may be identified by specific cell surface markers which are identified with unique monoclonal antibodies.
  • a method for obtaining a cell population enriched in mesenchymal stem cells is described, for example, in U.S. Patent No. 5,486,359.
  • Alternative sources for mesenchymal stem cells include, but are not limited to, blood, skin, cord blood, muscle, fat, bone, and perichondrium.
  • the mesenchymal stem cells may be administered by a variety of procedures.
  • the mesenchymal stem cells may be administered systemically, such as by intravenous, intraarterial, or intraperitoneal administration.
  • the mesenchymal stem cells may be from a spectrum of sources including autologous, allogeneic, or xenogeneic.
  • the mesenchymal stem cells are administered in an amount effective to treat an autoimmune disease in an animal.
  • the mesenchymal stem cells may be administered in an amount of from about 1x10° cells/kg to about 1x10 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the amount of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, the autoimmune disease to be treated, and the extent and severity thereof.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier.
  • the mesenchymal stem cells may be administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection.
  • a method of treating an inflammatory response in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to treat the inflammatory response in the animal.
  • the mesenchymal stem cells promote T-cell maturation to regulatory T-cells (T reg ), thereby controlling inflammatory responses. It is also believed that the mesenchymal stem cells inhibit T helper 1 cells (Th1 cells), thereby decreasing the expression of the Interferon- ⁇ (IFN- ⁇ ) in certain inflammatory reactions, such as those associated with psoriasis, for example.
  • T reg regulatory T-cells
  • IFN- ⁇ Interferon- ⁇
  • the inflammatory responses which may be treated are those associated with psoriasis.
  • the mesenchymal stem cells may be administered to an animal such that the mesenchymal stem cells contact microglia and/or astrocytes in the brain to reduce inflammation, whereby the mesenchymal stem cells limit neurodegeneration caused by activated glial cells in diseases or disorders such as Alzheimer's Disease, Parkinson's Disease, stroke, or brain cell injuries.
  • the mesenchymal stem cells may be administered to an animal such that the mesenchymal stem cells contact keratinocytes and Langerhans cells in the epidermis of the skin to reduce inflammation as may occur in psoriasis, chronic dermatitis, and contact dermatitis.
  • this embodiment is not to be limited to any theoretical reasoning, it is believed that the mesenchymal stem cells may contact the keratinocytes and Langerhans cells in the epidermis, and alter the expression of T- cell receptors and cytokine secretion profiles, leading to decreased expression of tumor necrosis factor-alpha (TNF- ⁇ ) and increased regulatory T-cell (Treg cell) population.
  • TNF- ⁇ tumor necrosis factor-alpha
  • Treg cell regulatory T-cell
  • the mesenchymal stem cells may be used to reduce inflammation in the bone, as occurs in arthritis and arthritis-like conditions, including but not limited to, osteoarthritis and rheumatoid arthritis, and other arthritic diseases listed in the website www.arthritis.org/conditions/diseases.
  • arthritis and arthritis-like conditions including but not limited to, osteoarthritis and rheumatoid arthritis, and other arthritic diseases listed in the website www.arthritis.org/conditions/diseases.
  • the mesenchymal stem cells may be used to limit inflammation in the gut and liver during inflammatory bowel disease and chronic hepatitis, respectively.
  • the scope of this aspect of the present invention is not intended to be limited to any theoretical reasoning, it is believed that the mesenchymal stem cells promote increased secretion of lnterleukin-10 (IL-10) and the generation of regulatory T-cells (Treg cells).
  • IL-10 lnterleukin-10
  • Treg cells regulatory T-cells
  • the mesenchymal stem cells may be used to inhibit excessive neutrophil and macrophage activation in pathological conditions such as sepsis and trauma, including burn injury, surgery, and transplants.
  • pathological conditions such as sepsis and trauma, including burn injury, surgery, and transplants.
  • the mesenchymal stem cells promote secretion of suppressive cytokines such as IL-10, and inhibit macrophage migration inhibitory factor.
  • the mesenchymal stem cells may be used to control inflammation in immune privileged sites such as the eye, including the cornea, lens, pigment epithelium, and retina, brain, spinal cord, pregnant uterus and placenta, ovary, testes, adrenal cortex, liver, and hair follicles.
  • immune privileged sites such as the eye, including the cornea, lens, pigment epithelium, and retina, brain, spinal cord, pregnant uterus and placenta, ovary, testes, adrenal cortex, liver, and hair follicles.
  • the mesenchymal stem cells may be used to control end-stage renal disease (ESRD) infections during dialysis and/or glomerulonephritis.
  • ESRD end-stage renal disease
  • mesenchymal stem cells induce peripheral blood mononuclear cells to express vascular endothelial growth factor, or VEGF, which stimulates glomerular structuring.
  • VEGF vascular endothelial growth factor
  • the mesenchymal stem cells may be used to control viral infections such as influenza, hepatitis C, Herpes Simplex Virus, vaccinia virus infections, and Epstein-Barr virus.
  • viral infections such as influenza, hepatitis C, Herpes Simplex Virus, vaccinia virus infections, and Epstein-Barr virus.
  • IFN- ⁇ Interferon-Beta
  • the mesenchymal stem cells may be used to control parasitic infections such as Leishmania infections and Helicobacter infections.
  • parasitic infections such as Leishmania infections and Helicobacter infections.
  • the scope of this embodiment is not to be limited to any theoretical reasoning, it is believed that the mesenchymal stem cells mediate responses by T helper 2 (Th2) cells, and thereby promote increased production of Immunogiobulin E (IgE) by ⁇ -cells. It is to be understood, however, that the scope of this aspect of the present invention is not to be limited to the treatment of any particular inflammatory response.
  • Th2 T helper 2
  • IgE Immunogiobulin E
  • the mesenchymal stem cells may be administered to a mammal, including human and non-human primates, as hereinabove described.
  • the mesenchymal stem cells also may be administered systemically, as hereinabove described.
  • the mesenchymal stem cells may be administered directly to an arthritic joint.
  • the mesenchymal stem cells are administered in an amount effective to treat an inflammatory response in an animal.
  • the mesenchymal stem cells may be administered in an amount of from about 1x10 5 cells/kg to about 1x10 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the exact dosage of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, the inflammatory response being treated, and the extent and severity thereof.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier, as hereinabove described.
  • a method of treating cancer in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to treat cancer in the animal.
  • the scope of this aspect of the present invention is not to be limited to any theoretical reasoning, it is believed that the mesenchymal stem cells interact with dendritic cells, which leads to IFN- ⁇ secretion, which in turn acts as a tumor suppressor.
  • Cancers which may be treated include, but are not limited to, hepatocellular carcinoma, cervical cancer, pancreatic cancer, prostate cancer, fibrosarcoma, medullablastoma, and astrocytoma. It is to be understood, however, that the scope of the present invention is not to be limited to any specific type of cancer.
  • the animal may be a mammal, including human and non-human primates, as hereinabove described.
  • the mesenchymal stem cells are administered to the animal in an amount effective to treat cancer in the animal.
  • the mesenchymal stem cells are administered in an amount of from about 1x10 5 cells/kg to about 1x10 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the exact amount of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, the type of cancer being treated, and the extent and severity thereof.
  • the mesenchymal stem cells are administered in conjunction with an acceptable pharmaceutical carrier, and may be administered sytemically, as hereinabove described. Alternatively, the mesenchymal stem cells may be administered directly to the cancer being treated.
  • a method of treating an allergic disease or disorder in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to treat the allergic disease or disorder in the animal.
  • mesenchymal stem cells when administered after an acute allergic response, provide for inhibition of mast cell activation and degranulation. Also, it is believed that the mesenchymal stem cells downregulate basophil activation and inhibit cytokines such as TNF- ⁇ , chemokines such as lnterleukin-8 and monocyte chemoattractant protein, or MCP-1 , lipid mediators such as leukotrienes, and inhibit main mediators such as histamine, heparin, chondroitin sulfates, and cathepsin.
  • cytokines such as TNF- ⁇
  • chemokines such as lnterleukin-8 and monocyte chemoattractant protein
  • MCP-1 monocyte chemoattractant protein
  • lipid mediators such as leukotrienes
  • main mediators such as histamine, heparin, chondroitin sulfates, and cathepsin.
  • Allergic diseases or disorders which may be treated include, but are not limited to, asthma, allergic rhinitis, atopic dermatitis, and contact dermatitis. It is to be understood, however, that the scope of the present invention is not to be limited to any specific allergic disease or disorder
  • the mesenchymal stem cells are administered to the animal in an amount effective to treat the allergic disease or disorder in the animal.
  • the animal may be a mammal.
  • the mammal may be a primate, including human and non-human primates.
  • the mesenchymal stem cells are administered in an amount of from about 1x10 5 cells/kg to about 1x10 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the exact dosage is dependent upon a variety of factors, including the age, weight, and sex of the patient, the allergic disease or disorder being treated, and the extent and severity thereof.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier, as hereinabove described.
  • the mesenchymal stem cells may be administered systemically, such as by intravenous or intraarterial administration, for example.
  • a method of promoting wound healing in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to promote wound healing in the animal.
  • the mesenchymal stem cells cause T reg cells and dendritic cells to release lnterleukin-10 (IL-10).
  • IL-10 lnterleukin-10
  • the IL-10 limits or controls inflammation in a wound, thereby promoting healing of a wound.
  • the mesenchymal stem cells may promote wound healing and fracture healing by inducing secretion factors by other cell types.
  • the mesenchymal stem cells may induce prostaglandin E2 (PGE 2 )-mediated release of vascular endothelial growth factor (VEGF) by peripheral blood mononuclear cells (PBMCs), as well as PGE 2 -mediated release of growth hormone, insulin, insulin-like growth factor 1 (IGF-1 ) insulin-like growth factor binding protein-3 (IGFBP-3), and endothelin-1.
  • PGE 2 prostaglandin E2
  • IGF-1 insulin-like growth factor 1
  • IGFBP-3 insulin-like growth factor binding protein-3
  • the mesenchymal stem cells are administered to the animal in an amount effective to promote wound healing in the animal.
  • the animal may be a mammal, and the mammal may be a primate, including human and non-human primates.
  • the mesenchymal stem cells are administered in an amount of from about 1x10 5 cells/kg to about 1x10 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the exact amount of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, and the extent and severity of the wound being treated.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier, as hereinabove described.
  • the mesenchymal stem cells may be administered systemically, as hereinabove described.
  • the mesenchymal stem cells may be administered directly to a wound, such as in a fluid on a dressing or reservoir containing the mesenchymal stem cells.
  • a method of treating or preventing fibrosis in an animal comprises administering to the animal mesenchymal stem cells in an amount effective to treat or prevent fibrosis in an animal.
  • the mesenchymal stem cells may be administered to the animal in order to treat or prevent any type of fibrosis in the animal, including, but not limited to, cirrhosis of the liver, fibrosis of the kidneys associated with end-stage renal disease, and fibrosis of the lungs. It is to be understood that the scope of the present invention is not to be limited to any specific type of fibrosis.
  • the mesenchymal stem cells are administered to the animal in an amount effective to treat or prevent fibrosis in the animal.
  • the animal may be a mammal, and the mammal may be a primate, including human and non-human primates.
  • the mesenchymal stem cells are administered in an amount of from about 1x10 5 cells/kg to about 1x1O 7 cells/kg, preferably from about 1x10 6 cells/kg to about 5x10 6 cells/kg.
  • the exact amount of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, and the extent and severity of the fibrosis being treated or prevented.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier, as hereinabove described.
  • the mesenchymal stem cells may be administered systemically, also as hereinabove described.
  • a method of promoting angiogenesis in an organ or tissue of an animal comprises administering to the animal mesenchymal stem cells in an amount effective to promote angiogenesis in an organ or tissue of the animal.
  • Angiogenesis is the formation of new blood vessels from a pre-existing microvascular bed.
  • angiogenesis may be used to treat coronary and peripheral artery insufficiency, and thus may be a noninvasive and curative approach to the treatment of coronary artery disease, ischemic heart disease, and peripheral artery disease.
  • Angiogenesis may play a role in the treatment of diseases and disorders in tissue and organs other than the heart, as well as in the development and/or maintenance of organs other than the heart.
  • Angiogenesis may provide a role in the treatment of internal and external wounds, as well as dermal ulcers.
  • Angiogenesis also plays a role in embryo implantation, and placental growth, as well as the development of the embryonic vasculature.
  • Angiogenesis also is essential for the coupling of cartilage resorption with bone formation, and is essential for correct growth plate morphogenesis.
  • angiogenesis is necessary for the successful engineering and maintenance of highly metabolic organs, such as the liver, where a dense vascular network is necessary to provide sufficient nutrient and gas transport.
  • the mesenchymal stem cells can be administered to the tissue or organ in need of angiogenesis by a variety of procedures.
  • the mesenchymal stem cells may be administered systemically, such as by intravenous, intraarterial, or intraperitoneal administration, or the mesenchymal stem cells may be administered directly to the tissue or organ in need of angiogenesis, such as by direct injection into the tissue or organ in need of angiogenesis.
  • the mesenchymal stem cells may be from a spectrum of sources including autologous, allogeneic, or xenogeneic.
  • PBMCs peripheral blood mononuclear cells
  • VEGF vascular endothelial growth factor
  • the animal is a mammal.
  • the mammal may be a primate, including human and non-human primates.
  • the mesenchymal stem cells may be employed in the treatment, alleviation, or prevention of any disease or disorder which can be alleviated, treated, or prevented through angiogenesis.
  • the mesenchymal stem cells may be administered to an animal to treat blocked arteries, including those in the extremities, i.e., arms, legs, hands, and feet, as well as the neck or in various organs.
  • the mesenchymal stem cells may be used to treat blocked arteries which supply the brain, thereby treating or preventing stroke.
  • the mesenchymal stem cells may be used to treat blood vessels in embryonic and postnatal corneas and may be used to provide glomerular structuring.
  • the mesenchymal stem cells may be employed in the treatment of wounds, both internal and external, as well as the treatment of dermal ulcers found in the feet, hands, legs or arms, including, but not limited to, dermal ulcers caused by diseases such as diabetes and sickle cell anemia.
  • the mesenchymal stem sells may be employed to promote embryo implantation and prevent miscarriage.
  • mesenchymal stem cells may be administered to an unborn animal, including humans, to promote the development of the vasculature in the unborn animal.
  • the mesenchymal stem cells may be administered to an animal, born or unborn, in order to promote cartilage resorption and bone formation, as well as promote correct growth plate morphogenesis.
  • the mesenchymal stem cells are administered in an amount effective in promoting angiogenesis in an animal.
  • the mesenchymal stem cells may be administered in an amount of from about 1x10 5 cells/kg to about 1x10 7 cells/kg, preferably from about 1x1O 6 cells/kg to about 5x10 6 cells/kg.
  • the amount of mesenchymal stem cells to be administered is dependent upon a variety of factors, including the age, weight, and sex of the patient, the disease or disorder to be treated, alleviated, or prevented, and the extent and severity thereof.
  • the mesenchymal stem cells may be administered in conjunction with an acceptable pharmaceutical carrier.
  • the mesenchymal stem cells may be administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection. Injection can be local, i.e., directly into the tissue or organ in need of angiogenesis, or systemic.
  • the mesenchymal stem cells may be genetically engineered with one or more polynucleotides encoding a therapeutic agent.
  • the polynucleotides may be delivered to the mesenchymal stem cells via an appropriate expression vehicle.
  • Expression vehicles which may be employed to genetically engineer the mesenchymal stem cells include, but are not limited to, retroviral vectors, adenoviral vectors, and adeno- associated virus vectors.
  • mesenchymal stem cells when employed in the above-mentioned therapies and treatments, may be employed in combination with other therapeutic agents known to those skilled in the art, including, but not limited to, growth factors, cytokines, drugs such as anti-inflammatory drugs, and cells other than mesenchymal stem cells, such as dendritic cells, and may be administered with soluble carriers for cells such as hyalurionic acid, or in combination with solid matrices, such collagen, gelatin, or other biocompatible polymers, as appropriate. It is to be understood that the methods described herein may be carried out in a number of ways and with various modifications and permutations thereof that are well known in the art.
  • Fig. 1 MSCs modulate dendritic cell functions.
  • A Flow cytometric analysis of mature monocytic DC1 cells using antibodies against HLA-DR and CD11c and of plasmacytoid DC2 cells using antibodies against HLA-DR and CD123 (IL-3 receptor).
  • B MSCs inhibit TNF- ⁇ secretion (primary y-axis) and increase IL-10 secretion (secondary y-axis) from activated DC1 and DC2 respectively.
  • C MSCs cultured with mature DC1 cells inhibit IFN- ⁇ secretion (primary y-axis) by T cells and increase IL-4 levels (secondary y-axis) as compared to MSC or DC alone.
  • Fig. 2 MSCs inhibit pro-inflammatory effector T cell function.
  • A Flow cytometric analysis of T Reg cell numbers (in %) by staining PBMCs or non-adherent fraction in MSC+PBMC culture (MSC+PBMC) with FITC-conjugated CD4 (x-axis) and PE conjugated CD25 (y-axis) antibodies. Gates were set based on isotype control antibodies as background. Graphs are representative of 5 independent experiments.
  • C MSCs inhibit IFN- ⁇ secretion from purified NK cells cultured for 0, 24, or 48 hours in a 24-well plate. Data shown are mean+SD cytokine secretion in one experiment and are representative of 3 independent experiments.
  • Fig. 3 MSCs lead to increased numbers of T reg cell population and increased GITR expression.
  • MLR mixed lymphocyte reaction
  • PHA phytohemagglutinin
  • PBMCs were cultured for 3 days in the absence (top plot) or presence (bottom plot) of MSCs (MSC to PBMC ratio 1 :10), following which the non-adherent fraction was harvested and immunostained with FITC-labeled GITR and PE-labeled CD4. Results show a greater than twofold increase in GITR expression in cells cultured in the presence of MSCs.
  • Fig. 4 MSCs produce PGE 2 and blocking PGE 2 reverses MSC-mediated immuno-modulatory effects .
  • A PGE 2 secretion (mean+SD) in culture supematants obtained from MSCs cultured in the presence or absence of PGE 2 blockers NS-398 or indomethacin (Indometh.) at various concentrations. Inhibitor concentrations are in ⁇ M and data presented are values obtained after 24 hour culture
  • B COX-1 and COX-2 expression in MSCs and PBMCs using real-time RT-PCR.
  • MSCs expressed significantly higher levels of COX-2 as compared to PBMCs, and when MSCs were cultured in presence of PBMCs, there was a >3-fold increase in COX-2 expression in MSCs. Representative data from 1 of 3 independent experiments is shown. The MSC+PBMC cultures were setup in a trans-well chamber plate where MSCs were plated onto the bottom chamber and PBMCs onto the top chamber.
  • C Presence of PGE 2 blockers indomethacin (Ind.) or NS-398 increases TNF- ⁇ secretion from activated DCs (D) and IFN- ⁇ secretion from TH1 cells (EH) as compared to controls.
  • Fig. 5 Constituitive MSC cytokine secretion is elevated in the presence of allogeneic PBMCs.
  • cytokines IL-6 and VEGF, lipid mediator PGE 2 , and matrix metalloproteinase 1 (pro- MMP-1) were analyzed.
  • pro- MMP-1 matrix metalloproteinase 1
  • MSCs produced IL-6, VEGF, and PGE 2 constituitively, and the levels of these factors increased upon co-culture with PBMCs, thereby suggesting that MSCs may play a role in modulating immune functions in an inflammatory setting.
  • Fig. 6 MSCs inhibit mitogen-induced T-cell proliferation in a dose- dependent manner. Increasing numbers of allogeneic PBMCs were incubated with constant numbers of MSCs (2,000 cells/well) plated on a 96-well plate in the presence or absence of PHA (2.5 mg/ml) for 72 hours, and 3 H thymidine incorporation determined (in counts per minute, or cpm).
  • Fig. 7 Schematic diagram of proposed MSC mechanism of action MSCs mediate their immuno-modulatory effects by affecting cells from both the innate (DCs- pathways 2-4; and NK- pathway 6) and adaptive (T- pathways 1 and 5 and B-pathway 7) immune systems.
  • immature DCs migrate to the site of potential entry, mature and acquire an ability to prime na ⁇ ve T cells (by means of antigen specific and co-stimulatory signals) to become protective effector T cells (cell-mediated T 1 or humoral TH2 immunity).
  • MSCs may alter the outcome of immune response by limiting the ability of DCs to mount a cell-mediated response (pathway 2) or by promoting the ability to mount a humoral response (pathway 4). Also, when mature effector T cells are present, MSCs may interact with them to skew the balance of TH1 (pathway 1 ) responses towards TH2 responses (pathway 5), and probably towards an increased IgE producing B cell activity (pathway 7), desirable outcomes for suppression of GvHD and autoimmune disease symptoms.
  • MSCs in their ability to result in an increased generation of T Reg population may result in a tolerant phenotype and may aid a recipient host by dampening bystander inflammation in their local micro-environment.
  • Dashed line ( — ) represents proposed mechanism.
  • MSCs Human MSCs were cultured as described by Pittenger et al., Science. Vol. 284, pg. 143 (1999). Briefly, marrow samples were collected from the iliac crest of anonymous donors following informed consent by Poietics Technologies, Div of Cambrex Biosciences. MSCs were cultured in complete Dulbecco's Modified Eagle's Medium-Low Glucose (Life Technologies, Carlsbad, California) containing 1 % antibiotic- antimyotic solution (Invitrogen, Carlsbad, California) and 10% fetal bovine serum (FBS, JRH BioSciences, Lenexa, Kansas).
  • Dulbecco's Modified Eagle's Medium-Low Glucose Life Technologies, Carlsbad, California
  • FBS fetal bovine serum
  • MSCs grew as an adherent monolayer and were detached with trypsin/EDTA (0.05% trypsin at 37°C for 3 minutes). All MSCs used were previously characterized for multilineage potential and retained the capacity to differentiate into mesenchymal lineages (chondrocytic, adipogenic, and osteogenic) (Pittenger, et al., Science. Vol. 284, pg. 143 (1999)).
  • PBMCs Peripheral blood mononuclear cells
  • DCs dendritic cells
  • CD1c + monocytic lineage
  • CD1c expressing B cells were magnetically depleted of CD19 + cells using magnetic beads, followed by labeling the B-cell depleted fraction with biotin- labeled CD1c (BDCA1 + ) and anti-biotin antibodies and separating them from the unlabeled cell fraction utilizing magnetic columns according to the manufacturer's instructions (Miltenyi Biotech, Auburn, California).
  • Precursors of DCs of plasmacytoid lineage were isolated from PBMCs by immuno-magnetic sorting of positively labeled antibody coated cells (BDCA2 + ) (Miltenyi Biotech, Auburn, California).
  • MSC-DC culture In most experiments, human MSCs and DCs were cultured in equal numbers for various time periods and cell culture supernatant collected and stored at -80°C until further evaluation. In selected experiments, MSCs were cultured with mature DC1 or DC2 cells (1 :1 MSC:DC ratio) for 3 days, and then the combined cultures (MSCs and DCs) were irradiated to prevent any proliferation. Next, antibody purified, na ⁇ ve, allogeneic T cells (CD4 + ,CD45RA + ) were added to the irradiated MSCs/DCs and cultured for an additional 6 days.
  • the non-adherent cell fraction (purified T cells) was then collected from the cultures, washed twice and re-stimulated with PHA for another 24 hours, following which cell culture supematants were harvested and analyzed for secreted IFN- ⁇ and IL-4 by ELISA.
  • NK cells Purified populations of NK cells were obtained by depleting non-NK cells that are magnetically labeled with a cocktail of biotin-conjugated monoclonal antibodies (anti - CD3, -CD14, -CD19, -CD36 and anti-lgE antibodies) as a primary reagent and anti- biotin monoclonal antibodies conjugated to Microbeads as secondary labeling reagent.
  • biotin-conjugated monoclonal antibodies anti - CD3, -CD14, -CD19, -CD36 and anti-lgE antibodies
  • the magnetically labeled non-NK cells were retained in MACS (Miltenyi Biotech, Auburn, California) columns in a magnetic field, while NK cells passed through and were collected.
  • T Reg cell population was isolated using a 2-step isolation procedure.
  • First non-CD4 + T cells were indirectly magnetically labeled with a cocktail of biotin labeled ⁇ antibodies and anti-biotin microbeads. The labeled cells were then depleted by separation over a MACS column (Miltenyi Biotech, Auburn, California).
  • CD4 + CD25 + cells were directly labeled with CD25 microbeads and isolated by positive selection from the pre-enriched CD4 + T cell fraction.
  • the magnetically labeled CD4 + CD25 + T cells were retained on the column and eluted after removal of the column from the magnetic field.
  • CD4+CD25+ T reg cell populations were isolated from PBMC or MSC+PBMC (MSC to PBMC ratio 1 :10) cultures (cultured without any further stimulation for 3 days) using a 2-step magnetic isolation procedure. These cells were irradiated to block any further proliferation and used as stimulators in a mixed lymphocyte reaction (MLR), where responders were allogeneic PBMCs (stimulator to responder ratio 1 :100) in the presence of PHA (2.5 ⁇ g/ml). The culture was carried out for 48 hours, following which 3 H thymidine was added. Incorporated radioactivity was counted after 24 hours.
  • MLR mixed lymphocyte reaction
  • PBMCs were cultured in the absence or presence of MSCs (MSC to PBMC ratio 1 :10), following which the non-adherent fraction was harvested and immunostained with FITC-labeled glucocorticoid-induced TNF receptor, or GITR, and PE -labeled CD4.
  • PBMCs Peripheral blood mononuclear cells
  • Non-adherent fraction was incubated in the presence of plate-bound anti-CD3 (5 ⁇ g/ml) and anti-CD28 (1 ⁇ g/ml) antibodies under T H 1 (IL-2 (4 ng/ml) + IL-12 (5 ng/ml) + anti-IL-4 (1 ⁇ g/ml)) or T H 2 (IL-2 (4 ng/ml) + IL-4 (4 ng/ml) + anti-IFN- ⁇ (1 ⁇ g/ml)) conditions for 3 days in the presence or absence of MSCs.
  • T H 1 IL-2 (4 ng/ml) + IL-12 (5 ng/ml) + anti-IL-4 (1 ⁇ g/ml)
  • T H 2 IL-2 (4 ng/ml) + IL-4 (4 ng/ml) + anti-IFN- ⁇ (1 ⁇ g/ml)
  • the cells were washed and then re-stimulated with PHA (2.5 ⁇ g/ml) for another 24 or 48 hours, following which levels of IFN- ⁇ and IL-4 were measured in culture supernatants by ELISA (R&D Systems, Minneapolis, Minnesota).
  • VEGF vascular endothelial growth factor
  • PGE 2 lipid mediator prostaglandin E 2
  • pro- MMP-1 matrix metalloproteinase 1
  • Quantitative RT-PCR Total RNA from cell pellets were prepared using a commercially available kit (Qiagen, Valencia, California) and according to the manufacturer's instructions. Contaminating genomic DNA was removed using the DNA-free kit (Ambion, Austin, Texas). Quantitative RT-PCR was performed on a MJ Research Opticon detection system (South San Francisco, California) using QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, California) with primers at concentration of 0.5 ⁇ M. Relative changes in expression levels in cells cultured under different conditions were calculated by the difference in Ct values (crossing point) using ⁇ -actin as internal control.
  • COX-1 and COX-2 specific primers were: COX-1 : 5'-CCG GAT GCC AGT CAG GAT GAT G-3'(forward), 5'-CTA GAC AGC CAG ATG CTG ACA G-3' (reverse); COX-2: 5'- ATC TAC CCT CCT CAA GTC CC-3'(forward), 5'-TAC CAG AAG GGC AGG ATA CAG-3' (reverse).
  • DC1 and DC2 precursor dendritic cells were isolated by immuno-magnetic sorting of BDCA1 + and BDCA2 + cells respectively and matured by incubation with GM-CSF and IL-4 (1x10 3 lU/ml and 1x10 3 lU/ml, respectively) for DC1 cells, or IL-3 (10 ng/ml) for DC2 cells.
  • GM-CSF and IL-4 (1x10 3 lU/ml and 1x10 3 lU/ml, respectively
  • IL-3 10 ng/ml
  • DC1 cells In the presence of the inflammatory agent bacterial lipopolysaccharide (LPS, 1 ng/ml), DC1 cells produced moderate levels of TNF- ⁇ but when MSCs were present (ratios examined 1 :1 and 1 :10), there was >50% reduction in TNF- ⁇ secretion (Fig. 1B).
  • DC2 cells produced IL-10 in the presence of LPS and its levels were increased greater than 2-fold upon MSC:DC2 co-culture (1 :1 ) (Fig. 1B). Therefore, the MSCs modified the cytokine profile of activated DCs in culture towards a more tolerogenic phenotype.
  • activated DCs when cultured with MSCs, were able to reduce IFN- ⁇ and increase IL-4 levels secreted by naive CD4 + T cells (Fig. 1C) suggesting a MSC- mediated shift from pro-inflammatory to anti-inflammatory T cell phenotype.
  • T Reg T-regulatory cells
  • the CD4 + CD25 + T Reg cell population generated in presence of MSCs expressed increased levels of gluocorticoid- induced TNF receptor (GITR), a cell surface receptor expressed on T Reg cell populations, and was suppressive in nature as it suppressed allogeneic T cell proliferation (Fig. 3A,B).
  • GITR gluocorticoid- induced TNF receptor
  • Fig. 3A,B a cell surface receptor expressed on T Reg cell populations
  • MSCs were investigated as to their direct ability to affect T cell differentiation. Using antibody selected purified T cells (CD4 + Th cells), IFN- ⁇ producing TH1 and IL-4 producing TH2 cells were generated in presence or absence of MSCs. When MSCs were present during differentiation, there was reduced IFN- ⁇ secretion by TH1 cells and increased IL-4 secretion by TH2 cells (Fig. 2B).
  • MSCs modify T-cell functions by soluble factor(s) (LeBlanc, et al., Exp. Hematol.. Vol. 31 , pg. 890 (2003); Tse, et al., Transplantation. Vol. 75, pg. 389 (2003). It was observed that the MSCs secreted several factors, including IL-6, prostaglandin E 2 , VEGF and proMMP-lconstitutively, and the levels of each increased upon culture with PBMCs (Fig. 5).
  • MSCs were cultured with activated dendritic cells (DC1) or TH1 cells in the presence of PGE 2 inhibitors NS-398 or indomethacin.
  • DC1s dendritic cells
  • NS-398 or indomethacin increased TNF- ⁇ secretion by DC1s, and IFN- ⁇ secretion from TH1 cells (Fig. 4C), respectively, suggesting that MSC effects on immune cell types may be mediated by secreted PGE 2 .
  • Recent studies have shown that MSCs inhibit T-cell proliferation induced by various stimuli (DeNicola, et al., Blood, Vol. 99, pg.
  • MSCs inhibit mitogen-induced T cell proliferation in a dose-dependent manner (Fig. 6) and when PGE 2 inhibitors NS-398 (5 ⁇ M) or indomethacin (4 ⁇ M) were present, there was a >70% increase in ( 3 H) thymidine incorporation by PHA-treated PBMCs in MSC containing cultures as compared to controls without inhibitors (Fig. 4D).
  • a model of MSC interaction with other immune cell types (Fig. 7) is proposed.
  • MSCs may interact with them directly and inhibit the pro-inflammatory IFN- ⁇ production (pathway 1 ) and promote regulatory T cell phenotype (pathway 3) and anti-inflammatory T H 2 cells (pathway 5).
  • MSCs can alter the outcome of the T cell immune response through DCs by secreting PGE 2 , inhibiting pro-inflammatory DC1 cells (pathway 2) and promoting anti-inflammatory DC2 cells (pathway 4) or regulatory DCs (pathway 3).
  • a shift towards TH2 immunity suggests a change in B cell activity towards increased generation of lgE/lgG1 subtype antibodies (pathway 7).
  • MSCs by their ability to inhibit IFN- ⁇ secretion from NK cells likely modify NK cell function (pathway 6).
  • This model of MSC:lmmune cell interactions is consistent with the experimentation performed in several other laboratories (LeBlanc, et al., Exp. Hematol.. Vol. 31 , pg. 890 (2003); Tse, et al., Transplantation. Vol. 75, pg. 389 (2003); DiNicola, et al., Blood. Vol. 99, pg. 3838 (2002)). Further examination of the proposed mechanisms is underway and animal studies are now necessary to examine the in vivo effects of MSC administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
PCT/US2005/008506 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor Ceased WO2005093044A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP05725577A EP1727892B1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
AU2005227295A AU2005227295A1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
ES05725577T ES2385450T3 (es) 2004-03-22 2005-03-15 Células madre mesenquimatosas y sus utilizaciones
EP14172800.6A EP2824174B1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
JP2007505005A JP2007530543A (ja) 2004-03-22 2005-03-15 間葉幹細胞及びその使用法
AT05725577T ATE556134T1 (de) 2004-03-22 2005-03-15 Mesenchymstammzellen und verwendungendafür
CA2564679A CA2564679C (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
EP14172807.1A EP2824175B2 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
EP18205743.0A EP3461884B1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
AU2009200019A AU2009200019B2 (en) 2004-03-22 2009-01-02 Mesenchymal stem cells and uses therefor
AU2010200916A AU2010200916A1 (en) 2004-03-22 2010-03-10 Mesenchymal stem cells and uses therefor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55511804P 2004-03-22 2004-03-22
US60/555,118 2004-03-22
US11/541,853 US20080213227A1 (en) 2004-03-22 2006-10-02 Mesenchymal stem cells and uses therefor

Publications (1)

Publication Number Publication Date
WO2005093044A1 true WO2005093044A1 (en) 2005-10-06

Family

ID=39772836

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/008506 Ceased WO2005093044A1 (en) 2004-03-22 2005-03-15 Mesenchymal stem cells and uses therefor
PCT/US2007/020724 Ceased WO2008042174A2 (en) 2004-03-22 2007-09-26 Mesenchymal stem cells and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/020724 Ceased WO2008042174A2 (en) 2004-03-22 2007-09-26 Mesenchymal stem cells and uses therefor

Country Status (8)

Country Link
US (21) US20050239897A1 (https=)
EP (10) EP2298864B1 (https=)
JP (2) JP2007530543A (https=)
KR (1) KR20090065478A (https=)
CN (1) CN101384702A (https=)
AU (3) AU2005227295A1 (https=)
CA (2) CA2564679C (https=)
WO (2) WO2005093044A1 (https=)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127408A3 (en) * 2006-04-28 2008-02-21 Tulane University Health Scien Methods for treating diabetes
WO2009031606A1 (ja) 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
WO2008116157A3 (en) * 2007-03-22 2009-03-19 Osiris Therapeutics Inc Mesenchymal stem cells and uses therefor
JP2009526768A (ja) * 2006-02-01 2009-07-23 サムソン ライフ パブリック ウェルフェア ファウンデーション 臍帯血から分離または、増殖された細胞を含む進行性、慢性肺疾患治療用組成物
EP2105498A1 (en) 2008-03-28 2009-09-30 JCR Pharmaceuticals CO., LTD. Therapeutic composition for atopic dermatitis
WO2010015929A2 (en) 2008-08-04 2010-02-11 Cellerix Sa Uses of mesenchymal stem cells
JP2010505764A (ja) * 2004-03-22 2010-02-25 オシリス セラピューティクス，インコーポレイティド 間葉系幹細胞とその用途
EP2223696A1 (en) * 2007-05-24 2010-09-01 Apceth GmbH & Co. KG Mesenchymal CD34- stem cells for use in wound healing gene therapy
WO2011049291A3 (ko) * 2009-10-23 2011-07-21 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
EP2465922A3 (en) * 2006-01-13 2012-12-05 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptor
US8481022B2 (en) 2007-08-09 2013-07-09 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2013146992A1 (ja) 2012-03-29 2013-10-03 日本ケミカルリサーチ株式会社 歯髄由来の多能性幹細胞の製造方法
WO2014100857A1 (en) * 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
WO2016001846A1 (en) * 2014-06-30 2016-01-07 Tigenix S.A.U. Mesenchymal stromal cells for treating sepsis
CN105658069A (zh) * 2013-11-04 2016-06-08 贝克顿·迪金森公司 多潜能基质细胞(msc)群体的免疫调节潜力
EP2318519B1 (en) 2008-08-14 2016-10-05 Mesoblast International Sàrl Purified mesenchymal stem cell compositions
EP3109317A1 (en) 2007-10-17 2016-12-28 TXCell Tr1 cells, mesenchymal stem cells and uses thereof
AU2015268704B2 (en) * 2008-08-04 2017-08-10 Consejo Superior De Investigaciones Cientificas Uses of mesenchymal stem cells
US10357518B2 (en) 2016-03-14 2019-07-23 Tigenix S.A.U. Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
US10548924B2 (en) 2004-08-25 2020-02-04 Tigenix, S.A.U. Use of adipose tissue-derived stromal stem cells in treating fistula
WO2020182935A1 (en) * 2019-03-12 2020-09-17 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
US11174461B2 (en) 2016-03-16 2021-11-16 Cynata Therapeutics Limited Colony forming medium and use thereof
US20230137723A1 (en) * 2021-11-01 2023-05-04 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
US11708560B2 (en) 2010-10-08 2023-07-25 Mesoblast International Sarl Enhanced MSC preparations
EP4137141A4 (en) * 2020-04-13 2024-04-24 National University Corporation Tokai National Higher Education and Research System AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN THE KIDNEY
RU2828728C2 (ru) * 2019-03-12 2024-10-17 Бёрингер Ингельхайм Вэтэринари Мэдсин Белджиум Иммуномодулирующие мезенхимальные стволовые клетки
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
US12186344B2 (en) 2005-09-23 2025-01-07 Tigenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US12473547B2 (en) 2017-11-22 2025-11-18 Mesoblast International Sàrl Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
AUPR298901A0 (en) 2001-02-07 2001-03-08 McComb Foundation, Inc., The Cell suspension preparation technique and device
ES2432493T3 (es) 2001-02-14 2013-12-03 Anthrogenesis Corporation Placenta de mamífero post-parto, su uso y células madre de la misma
EP2316918B1 (en) * 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
ATE556134T1 (de) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc Mesenchymstammzellen und verwendungendafür
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
EP1976978A2 (en) 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
US20070207130A1 (en) * 2006-03-01 2007-09-06 Calvin Cao Stem cell therapy to treat symptoms of avian flu and other diseases
US9598673B2 (en) * 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
CA2677679A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US8983570B2 (en) 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US11224635B2 (en) * 2007-03-27 2022-01-18 Venturis Thereuptics, Inc. Therapeutic angiogenesis for treatment of the spine and other tissues
US20080254005A1 (en) * 2007-04-06 2008-10-16 Medistem Labortories Stem Cell Therapy for the Treatment of Autism and Other Disorders
US20080260703A1 (en) * 2007-04-23 2008-10-23 Medistem Labortories Treatment of Insulin Resistance and Diabetes
NZ582616A (en) * 2007-06-15 2012-07-27 Garnet Biotherapeutics Inc Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
AU2008299318A1 (en) * 2007-09-12 2009-03-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating tumors in immune-privileged sites
KR20140107677A (ko) 2007-09-19 2014-09-04 플루리스템 리미티드 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
WO2009046377A2 (en) * 2007-10-04 2009-04-09 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US20110020291A1 (en) * 2007-11-17 2011-01-27 Debrabrata Banerjee Use of stem cells for wound healing
CA2710081C (en) * 2007-12-21 2015-11-24 Bone Therapeutics S.A. Human bone-forming cells in the treatment of inflammatory rheumatic diseases
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
KR20100054711A (ko) * 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
US8343480B2 (en) * 2008-11-14 2013-01-01 Howmedica Osteonics Corp. Administration of stem or progenitor cells to a joint to enhance recovery from joint surgery
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US8309343B2 (en) 2008-12-01 2012-11-13 Baxter International Inc. Apparatus and method for processing biological material
US10098333B2 (en) * 2008-12-09 2018-10-16 University Of Southern California Method for treating an SLE-like autoimmune disease in a human subject consisting of administering stem cells from human exfoliated deciduous teeth (SHED) and erythropoietin (EPO) to said human subject
MX353489B (es) 2009-07-02 2018-01-16 Anthrogenesis Corp Metodo para producir eritrocitos sin celulas alimentadoras.
SG178064A1 (en) * 2009-07-21 2012-03-29 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
WO2011020095A2 (en) * 2009-08-14 2011-02-17 Case Western Reserve University Compositions and methods of treating inflammation
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
CN102048756B (zh) * 2009-11-04 2014-02-19 中国医学科学院基础医学研究所 人脂肪来源的间充质干细胞在肾脏、眼底疾病中的用途
US20130129686A1 (en) * 2009-11-19 2013-05-23 Regents Of The University Reducing Inflammation Using Cell Therapy
CN102471753B (zh) * 2009-12-08 2014-10-22 伊利诺伊大学理事会 干细胞免疫调节应用方法和设备
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
WO2011106521A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of macrophage activation
DK2556145T3 (en) 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
EP2575831B1 (en) * 2010-05-27 2016-04-20 Pluristem Ltd. Skeletal muscle regeneration using mesenchymal stem cells
US20120020931A1 (en) * 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
WO2012009581A2 (en) * 2010-07-14 2012-01-19 University Of Southern California Pharmaceutical compositions comprising gingiva-derived mesenchymal stem cells and methods of treating inflammation, wound healing and contact hypersensitivity
WO2012030968A1 (en) * 2010-08-31 2012-03-08 Renovocyte, LLC Systemic, allogenic stem cell therapies for treatment of diseases in animals
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2663316A2 (en) * 2011-01-12 2013-11-20 TiGenix, S.A.U. Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
KR20140004724A (ko) 2011-01-19 2014-01-13 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 전분화능을 위한 선천적 잠재력을 갖는 체세포
KR20120095022A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
US8709401B2 (en) 2011-02-25 2014-04-29 Howmedica Osteonics Corp. Primed stem cells and uses thereof to treat inflammatory conditions in joints
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR102246369B1 (ko) 2011-11-30 2021-04-29 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
BR112014013757A2 (pt) 2011-12-09 2019-08-27 Metabolic Pharmaceuticals Pty Ltd método para tratar osteoartrite; método para tratar uma condição que envolve condrócitos funcionais insuficientes ou tecido cartilaginoso funcional insuficiente; e uso de um peptídeo
CN102552880A (zh) * 2011-12-14 2012-07-11 南方医科大学 一种促进皮肤创面愈合的生物制剂
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
HK1207662A1 (en) * 2012-03-22 2016-02-05 AVITA Medical Americas, LLC Cell suspension and use thereof
US9745551B2 (en) 2012-07-12 2017-08-29 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2014018230A2 (en) * 2012-07-25 2014-01-30 Albert Einstein College Of Medicine Of Yeshiva University Methods to isolate human mesenchymal stem cells
CN103585177A (zh) * 2012-08-13 2014-02-19 首都医科大学附属北京口腔医院 间充质干细胞和基因修饰的间充质干细胞的用途
WO2014113704A2 (en) * 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
DK2956543T3 (da) 2013-02-12 2019-01-02 Replicel Life Sciences Inc Sammensætninger og fremgangsmåder til behandling og reparation af sener
US20140271568A1 (en) * 2013-03-12 2014-09-18 Hawking Biological Technology Co., Ltd Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
AU2013205148B2 (en) 2013-03-14 2014-10-30 AVITA Medical Americas, LLC Systems and methods for tissue processing and preparation of cell suspension therefrom
EP2972368B1 (en) * 2013-03-15 2019-07-24 TiGenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to cell therapy
JP6666240B2 (ja) 2013-04-12 2020-03-13 フランチェスカ， サベリオ ラ 移植のための臓器の改良
CN104138391B (zh) * 2013-05-08 2018-07-31 中国科学院上海生命科学研究院 间充质干细胞在预防或治疗应激反应导致的免疫力下降中的应用
US20160129531A1 (en) * 2014-01-13 2016-05-12 Camarc Llc Electrode of a welding torch
TW201538730A (zh) 2014-02-12 2015-10-16 Replicel Life Sciences Inc 用於治療骨骼、關節及軟骨之組合物及方法
US10624930B2 (en) * 2014-06-10 2020-04-21 Mesoblast International Sarl Treatment of immune disorders
JP6452107B2 (ja) 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
TWI625391B (zh) * 2014-09-17 2018-06-01 國璽幹細胞應用技術股份有限公司 藁本內酯之應用
US20160095885A1 (en) 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104357383A (zh) * 2014-10-11 2015-02-18 张炳强 人脂肪间充质干细胞制备方法及其在制备疾病药物的应用
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
WO2016153847A1 (en) * 2015-03-20 2016-09-29 Rediens, Inc. Bony tissue delivery systems and methods
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
EP3286562B1 (en) * 2015-04-24 2020-08-12 TiGenix, S.A.U. Biomarkers for determining the clinical response to cell therapy
WO2017048097A1 (ko) 2015-09-15 2017-03-23 주식회사 강스템바이오텍 Sod3를 과발현하는 줄기세포를 유효성분으로 포함하는 염증성 질환의 예방 또는 치료용 조성물
EP3922253A1 (en) 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
KR20180102661A (ko) * 2016-01-21 2018-09-17 에이비티 홀딩 컴퍼니 상처 치유를 위한 줄기 세포
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
WO2017221879A1 (ja) * 2016-06-20 2017-12-28 富士フイルム株式会社 トロフィックファクタ放出剤および炎症疾患処置剤
KR101816246B1 (ko) * 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
US10987381B2 (en) * 2017-01-27 2021-04-27 Neil Riordan Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis
JP7174758B2 (ja) 2017-07-14 2022-11-17 オーブセン セラピューティクス リミテッド Ｃｄ３９間質幹細胞の単離方法と使用
US20200339947A1 (en) 2017-12-22 2020-10-29 Chiesi Farmaceutici S.P.A. Mesenchymal stromal cells and methods for obtaining mesenchymal stromal cells from umbilical cord
WO2019132026A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
JP7217533B2 (ja) * 2018-01-24 2023-02-03 学校法人順天堂大学 間葉系幹細胞による処置の効果を増幅するための組成物
US20210154230A1 (en) * 2018-05-04 2021-05-27 Spinalcyte, Llc Intradiscal t-regulatory cell administration for treatment of disc degenerative disease
CN108646035B (zh) * 2018-05-18 2021-06-11 北京亦科诺生物科技有限公司 胰岛素样生长因子1的新应用
JP7480454B2 (ja) * 2018-06-05 2024-05-10 メディポスト・カンパニー・リミテッド 有効成分として間葉系幹細胞を含む炎症性疾患の予防又は治療のための医薬組成物
WO2019240962A1 (en) * 2018-06-14 2019-12-19 Abraham J And Phyllis Katz Cord Blood Foundation Isolation of mesenchymal stromal cells from umbilical cord blood
JP7132465B2 (ja) * 2018-10-04 2022-09-07 国立研究開発法人物質・材料研究機構 血管新生促進剤、及び治療方法
US20220333197A1 (en) * 2019-01-31 2022-10-20 Primegen Biotech, Llc Treatment of Atopic Dermatitis Using Mesenchymal Stem Cells and Immune Modulation
TW202045716A (zh) * 2019-02-28 2020-12-16 澳大利亞商辛那塔治療有限公司 用於改善間葉幹細胞之血管生成潛力的方法
DE102019106651A1 (de) * 2019-03-15 2020-09-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlungsvorrichtung und -verfahren zur extrakorporalen, Immuntoleranz-steigernden Blutbehandlung
WO2020190023A2 (ko) * 2019-03-19 2020-09-24 에스씨엠생명과학 주식회사 단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법
RU2704322C1 (ru) * 2019-06-11 2019-10-28 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте
WO2020251020A1 (ja) 2019-06-14 2020-12-17 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
BR112022017557A2 (pt) * 2020-03-05 2022-12-27 Mesoblast Int Sarl Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal
EP4146787A4 (en) 2020-05-08 2024-06-26 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
CN111557952A (zh) * 2020-05-28 2020-08-21 澳门大学 间充质干细胞在制备用于促进脂肪移植的制剂中的应用
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
JP2024517954A (ja) * 2021-05-13 2024-04-23 プライムジェン ユーエス インコーポレイテッド 肝疾患を治療するための方法および組成物
CN114736852A (zh) * 2022-06-13 2022-07-12 南京艾尔普再生医学科技有限公司 一种心肌细胞移植免疫排斥反应的体外实验模型
US12570949B2 (en) 2022-12-27 2026-03-10 AVITA Medical Americas, LLC Systems and devices for wound therapy and related methods of use
US12180456B2 (en) 2022-12-27 2024-12-31 AVITA Medical Americas, LLC Tissue healing
USD1112812S1 (en) 2023-12-22 2026-02-10 AVITA Medical Americas, LLC Tissue processing cartridge
CN119235919B (zh) * 2024-12-06 2025-04-11 四川华大生命科技有限公司 一种用于修复糖尿病创面的干细胞培养物制剂的制备方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000049136A1 (en) 1999-02-17 2000-08-24 United States Surgical Genetically altered mesenchymal stem cells and methods of use thereof
WO2001080865A2 (en) 2000-04-25 2001-11-01 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
US6355239B1 (en) * 1998-03-13 2002-03-12 Osiris Therapeutics, Inc. Uses for non-autologous mesenchymal stem cells
US20020037278A1 (en) * 2000-07-26 2002-03-28 Takafumi Ueno Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020044923A1 (en) * 1998-04-03 2002-04-18 Joseph D. Mosca Mesenchymal stem cells as immunosuppressants
US20020110544A1 (en) 1998-05-13 2002-08-15 Victor M. Goldberg Osteoarthritis cartilage regeneration
WO2003004661A2 (en) 2001-07-06 2003-01-16 Crucell Holland B.V. Adenovital vectors with cell type specificity for mesenchymal cells
EP1279738A1 (en) 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
WO2003059276A2 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2003068248A1 (en) 2002-02-12 2003-08-21 Intercytex Limited Cell delivery system
WO2003078609A1 (en) 2002-03-15 2003-09-25 Monash University Methods of inducing differentiation of stem cells into a specific cell lineage
WO2003105908A2 (en) 2002-03-15 2003-12-24 Department Of Veterans Affairs, Rehabilitation R & D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
WO2004006942A1 (en) 2002-07-12 2004-01-22 Boston Scientific Limited Method for sustaining direct cell delivery
KR20040016785A (ko) 2002-08-17 2004-02-25 서해영 간엽 줄기세포를 신경세포로 분화시키는 방법

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0651641B2 (ja) * 1983-08-29 1994-07-06 株式会社ミドリ十字 ガンマ・インターフェロン組成物
JPS6048933U (ja) 1983-09-12 1985-04-06 株式会社大隈鐵工所 研削盤ベツド上面のしぶき止めカバ−
JPH01501792A (ja) 1986-03-17 1989-06-22 シェリング・コーポレーション γ型インターフェロンによる癌の治療
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
CA2109729A1 (en) * 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
US5382514A (en) 1992-03-31 1995-01-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services In vivo angiogenesis assay
DK0871457T3 (da) 1995-03-28 2003-07-28 Univ Jefferson Isolerede stromaceller og fremgangsmåder til anvendelse heraf
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
AU2808397A (en) * 1996-04-26 1997-11-19 Case Western Reserve University Skin regeneration using mesenchymal stem cells
US6165785A (en) 1996-05-24 2000-12-26 University Of Cincinnati Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
CA2271758A1 (en) * 1996-11-15 1998-05-22 Osiris Therapeutics, Inc. Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
AU755888B2 (en) * 1998-03-18 2003-01-02 Mesoblast International Sarl Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
AU2904199A (en) * 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
ATE382681T1 (de) * 1998-07-31 2008-01-15 Genzyme Corp Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
US20050153442A1 (en) * 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
BR0008552A (pt) * 1999-03-10 2002-05-07 Univ Pittsburgh Células tronco e redes derivadas de tecido adiposo
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CN1307303C (zh) * 2000-01-19 2007-03-28 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
JP2004505886A (ja) † 2000-02-18 2004-02-26 スィーヴィー　セラピューティクス　インコーポレイテッド 鬱血性心不全の処置における部分的な脂肪酸酸化阻害剤
ES2300320T3 (es) 2000-02-26 2008-06-16 Artecel, Inc. Celulas madre pluripotentes generadas a partir de celulas del estroma derivadas de tejido adiposo y sus usos.
US6936281B2 (en) * 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
ATE359094T1 (de) * 2001-02-14 2007-05-15 Genzyme Corp Biokompatibles vlies für hämostase und gewebeaufbau
ATE421991T1 (de) 2001-04-24 2009-02-15 Ajinomoto Kk Stammzellen und verfahren zu deren trennung
US6549704B2 (en) 2001-06-26 2003-04-15 Corning Incorporated Fabrication of microlensed fiber using doped silicon dioxide
EP1430115A1 (en) * 2001-07-27 2004-06-23 Arhus Amt Immortilized stem cells
EP1433487A1 (en) * 2001-08-22 2004-06-30 National Institute of Advanced Industrial Science and Technology Method of bone regeneration
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
KR20050044393A (ko) 2001-11-09 2005-05-12 아르테셀 사이언스, 인크. 지방 조직 유래된 스트로마 세포의 내분비 췌장 분화 및이의 용도
US6939863B2 (en) 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
KR20040081749A (ko) * 2002-01-14 2004-09-22 헨리 포드 헬쓰 시스템 혈관을 형성하고 혈관신생 및 영양 인자를 생성시키는데사용하기 위한 골수 기질 세포로부터의 물질
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
WO2003082305A1 (en) * 2002-04-03 2003-10-09 Naohide Yamashita Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells
ITTO20020311A1 (it) 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1187058C (zh) * 2002-04-16 2005-02-02 中国医学科学院血液学研究所泰达生命科学技术研究中心 用于修复中枢神经损伤的干细胞制剂及其制造方法
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP1551955A4 (en) * 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
EP1545219A4 (en) 2002-07-23 2009-09-30 Boston Scient Ltd CELL THERAPY FOR REGENERATION
JP2005534345A (ja) * 2002-07-29 2005-11-17 エス セル インターナショナル ピーティーイー リミテッド インスリン陽性、グルコース応答性細胞の分化のための多段階方法
JP3897343B2 (ja) * 2002-08-01 2007-03-22 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
KR20040022134A (ko) * 2002-09-06 2004-03-11 송준석 인간 간엽줄기 세포와 p53 분비 아데노바이러스를 이용한항암치료방법
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
WO2004052177A2 (en) 2002-12-05 2004-06-24 Case Western Reserve University Cell-based therapies for ischemia
WO2004084950A2 (en) * 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
CN1536075A (zh) * 2003-04-09 2004-10-13 中国人民解放军军事医学科学院野战输 一种诱导骨髓间充质干细胞向胰岛样细胞分化的方法
EP2399990B1 (en) * 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
WO2005013885A2 (en) * 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
DE112004002222T5 (de) * 2003-11-20 2006-10-19 Advantest Corporation Taktwiedergewinnungsschaltung und Kommunikationsvorrichtung
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298864B1 (en) 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
ATE556134T1 (de) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc Mesenchymstammzellen und verwendungendafür
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
US7405186B2 (en) 2005-03-25 2008-07-29 Chemsil Silicones, Inc. Lubricant compositions, condom products and methods of making same
JP5162756B2 (ja) 2005-04-14 2013-03-13 財団法人ヒューマンサイエンス振興財団 医薬組成物及びその製造方法
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
WO2007124594A1 (en) 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
CN101523982B (zh) 2006-10-06 2012-03-14 皇家飞利浦电子股份有限公司 用于灯元件的电源设备以及用于给灯元件供电的方法
CA2674028C (en) 2008-07-25 2012-09-04 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Recombinant b. pseudomallei adhesin protein and methods and uses thereof
WO2010019886A1 (en) 2008-08-14 2010-02-18 Osiris Therapeutics, Inc. Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355239B1 (en) * 1998-03-13 2002-03-12 Osiris Therapeutics, Inc. Uses for non-autologous mesenchymal stem cells
US20020044923A1 (en) * 1998-04-03 2002-04-18 Joseph D. Mosca Mesenchymal stem cells as immunosuppressants
US20020110544A1 (en) 1998-05-13 2002-08-15 Victor M. Goldberg Osteoarthritis cartilage regeneration
WO2000049136A1 (en) 1999-02-17 2000-08-24 United States Surgical Genetically altered mesenchymal stem cells and methods of use thereof
WO2001080865A2 (en) 2000-04-25 2001-11-01 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
US20020037278A1 (en) * 2000-07-26 2002-03-28 Takafumi Ueno Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
WO2003004661A2 (en) 2001-07-06 2003-01-16 Crucell Holland B.V. Adenovital vectors with cell type specificity for mesenchymal cells
EP1279738A1 (en) 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US20030049843A1 (en) 2001-07-07 2003-03-13 Havenga Menzo Jans Emco Gene delivery vectors with cell type specificity for mesenchymal stem cells
WO2003059276A2 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2003068248A1 (en) 2002-02-12 2003-08-21 Intercytex Limited Cell delivery system
WO2003078609A1 (en) 2002-03-15 2003-09-25 Monash University Methods of inducing differentiation of stem cells into a specific cell lineage
WO2003105908A2 (en) 2002-03-15 2003-12-24 Department Of Veterans Affairs, Rehabilitation R & D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
WO2004006942A1 (en) 2002-07-12 2004-01-22 Boston Scientific Limited Method for sustaining direct cell delivery
KR20040016785A (ko) 2002-08-17 2004-02-25 서해영 간엽 줄기세포를 신경세포로 분화시키는 방법

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
BALLAS ET AL., J. CELL. BIOCHEM. SUPPL., vol. 38, 2002, pages 20
BARTHOLOMEW ET AL., EXP. HEMATOL., vol. 30, 2002, pages 42
CHOPP ET AL., NEUROREPORT, vol. 11, 2000, pages 3001
DEKOK ET AL., CLIN. ORAL IMPLANTS RES., vol. 14, 2003, pages 481
DEVINE, CANCER J., vol. 7, 2001, pages 576
DINICOLA ET AL., BLOOD, vol. 99, 2002, pages 3838
DZIONEK, J. IMMUNOL., vol. 165, 2000, pages 6037
EAVES ET AL., ANN. N.Y. ACAD. SCI., vol. 938, 2001, pages 63
FAKUDA, ARTIF. ORGANS, vol. 25, 2001, pages 187
FRASSONI ET AL., INT. SOCIETY FOR CELL THERAPY, 2002, pages SA006
HAYNESWORTH ET AL., BONE, vol. 13, 1992, pages 69
HAYNESWORTH ET AL., J. CELL. PHYSIOL., vol. 166, 1996, pages 585
HOROWITZ ET AL., PROC. NAT. ACAD. SCI., vol. 99, 2002, pages 8932
HORWITZ ET AL., BLOOD, vol. 97, 2001, pages 1227
KINGSLEY ET AL., J. IMMUNOL., vol. 168, 2002, pages 1080
KOC ET AL., J. CLIN. ONCOL., vol. 18, 2000, pages 307
LE BLANC ET AL., EXP. HEMATOL., vol. 31, 2003, pages 890
LEBLANC ET AL., SCAND J. IMMUNOL., vol. 57, 2003, pages 11
MACKENZIE ET AL., BLOOD CELLS MOL. DIS., vol. 27, 2002
MAJUMDAR ET AL., HEMATOTHER. STEM CELL RES., vol. 9, 2000, pages 841
MAJUMDAR ET AL., J. BIOMED. SCI., vol. 10, 2003, pages 228
NOEL ET AL., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 1000
PEREIRA ET AL., PROC. NAT. ACAD. SCI., vol. 95, 1998, pages 1142
PITTENGER ET AL., SCIENCE, vol. 284, 1999, pages 143
POTIAN ET AL., J. IMMUNOL., vol. 171, 2003, pages 3426
PROCKOP, SCIENCE, vol. 276, 1997, pages 71
SANCHEZ-RAMOS ET AL., EXP. NEUROL., vol. 171, 2001, pages 109
SCHWARTZ ET AL., HUM. GENE THER., vol. 10, 1999, pages 2539
See also references of EP1727892A4
SHAKE ET AL., ANN. THORAC. SURA., vol. 73, 2002, pages 1919
TOMA ET AL., CIRCULATION, vol. 105, 2002, pages 93
TOMITA ET AL., CIRCULATION, vol. 100, 1999, pages 247
TSE ET AL., TRANSPLANTATION, vol. 75, 2003, pages 389
WAGERS ET AL., GENE THERAPY, vol. 9, 2002, pages 606
WAKITANI ET AL., MUSCLE NERVE, vol. 18, 1995, pages 1417
WOODBURY ET AL., J. NEUROSCI. RES., vol. 69, 2002, pages 908
WU ET AL., J. NEUROSCI. RES., vol. 72, 2003, pages 393
WU ET AL., TRANSPLANTATION, vol. 75, 2003, pages 679

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298863A2 (en) 2004-03-22 2011-03-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
US10828334B1 (en) 2004-03-22 2020-11-10 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US9694035B2 (en) 2004-03-22 2017-07-04 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
US10960025B2 (en) 2004-03-22 2021-03-30 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10716814B2 (en) 2004-03-22 2020-07-21 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10729727B2 (en) 2004-03-22 2020-08-04 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
EP2824174B1 (en) 2004-03-22 2018-11-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US11389484B2 (en) 2004-03-22 2022-07-19 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
JP2010505764A (ja) * 2004-03-22 2010-02-25 オシリス セラピューティクス，インコーポレイティド 間葉系幹細胞とその用途
US9943547B2 (en) 2004-03-22 2018-04-17 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10548924B2 (en) 2004-08-25 2020-02-04 Tigenix, S.A.U. Use of adipose tissue-derived stromal stem cells in treating fistula
US10780132B2 (en) 2004-08-25 2020-09-22 Tigenix, S.A.U. Use of adipose tissue-derived stromal stem cells in treating fistula
US11672831B2 (en) 2005-06-24 2023-06-13 Takeda Pharmaceutical Company Limited Use of adipose tissue-derived stromal stem cells in treating fistula
US11660318B2 (en) 2005-06-24 2023-05-30 Takeda Pharmaceutical Company Limited Use of adipose tissue-derived stromal stem cells in treating fistula
US10758575B2 (en) 2005-06-24 2020-09-01 Tigenix, S.A.U. Use of adipose tissue-derived stromal stem cells in treating fistula
US12186344B2 (en) 2005-09-23 2025-01-07 Tigenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US8486695B2 (en) 2006-01-13 2013-07-16 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US11821004B2 (en) 2006-01-13 2023-11-21 Mesoblast International Sárl Mesenchymal stem cells expressing TNF-α receptors
EP3287520A1 (en) * 2006-01-13 2018-02-28 Mesoblast International Sàrl Mesenchymal stem cells expressing tnf-alpha receptors
EP2465922A3 (en) * 2006-01-13 2012-12-05 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptor
JP2009526768A (ja) * 2006-02-01 2009-07-23 サムソン ライフ パブリック ウェルフェア ファウンデーション 臍帯血から分離または、増殖された細胞を含む進行性、慢性肺疾患治療用組成物
US9498497B2 (en) 2006-02-01 2016-11-22 Medipost Co., Ltd. Method of treating lung diseases using cells separated or proliferated from umbilical cord blood
JP2009535347A (ja) * 2006-04-28 2009-10-01 テュレーン・ユニバーシティ・ヘルス・サイエンシーズ・センター 糖尿病の治療方法
WO2007127408A3 (en) * 2006-04-28 2008-02-21 Tulane University Health Scien Methods for treating diabetes
JP2010522212A (ja) * 2007-03-22 2010-07-01 オシリス セラピューティクス，インコーポレイティド 間充織幹細胞とその使用
EP3095450A1 (en) * 2007-03-22 2016-11-23 Mesoblast International Sàrl Mesenchymal stem cells for use in improving pulmonary function
EP2123747A1 (en) * 2007-03-22 2009-11-25 Osiris Therapeutics, Inc. Mesenchymal stem cells for use in treating a pulmonary disease or in reducing scar tissue
EP3653217A1 (en) * 2007-03-22 2020-05-20 Mesoblast International Sàrl Mesenchymal stem cells for use in improving pulmonary function
JP2014224117A (ja) * 2007-03-22 2014-12-04 メゾブラスト・インターナショナル・ソシエテ・ア・レスポンサビリテ・リミテ 間充織幹細胞とその使用
WO2008116157A3 (en) * 2007-03-22 2009-03-19 Osiris Therapeutics Inc Mesenchymal stem cells and uses therefor
EP4438721A3 (en) * 2007-03-22 2025-04-02 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP3973970A1 (en) * 2007-03-22 2022-03-30 Mesoblast International Sàrl Mesenchymal stem cells for use in treating idiopathic pulmonary fibrosis
EP2223696A1 (en) * 2007-05-24 2010-09-01 Apceth GmbH & Co. KG Mesenchymal CD34- stem cells for use in wound healing gene therapy
US7998472B2 (en) 2007-05-24 2011-08-16 Apceth Gmbh & Co. Kg CD34 stem cell-related methods and compositions
EP2851422A3 (en) * 2007-05-24 2015-06-24 Apceth GmbH & Co. KG CD34neg stem cells for the treatment of gastrointestinal disorders
US8481022B2 (en) 2007-08-09 2013-07-09 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009031606A1 (ja) 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
EP3109317A1 (en) 2007-10-17 2016-12-28 TXCell Tr1 cells, mesenchymal stem cells and uses thereof
EP2105498A1 (en) 2008-03-28 2009-09-30 JCR Pharmaceuticals CO., LTD. Therapeutic composition for atopic dermatitis
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
AU2009278853B2 (en) * 2008-08-04 2015-09-17 Consejo Superior De Investigaciones Cientificas Uses of mesenchymal stem cells
WO2010015929A3 (en) * 2008-08-04 2010-04-29 Cellerix Sa Uses of mesenchymal stem cells
AU2015268704B2 (en) * 2008-08-04 2017-08-10 Consejo Superior De Investigaciones Cientificas Uses of mesenchymal stem cells
WO2010015929A2 (en) 2008-08-04 2010-02-11 Cellerix Sa Uses of mesenchymal stem cells
EP3095449A1 (en) * 2008-08-04 2016-11-23 TiGenix, S.A.U. Uses of mesenchymal stem cells
EP2318519B1 (en) 2008-08-14 2016-10-05 Mesoblast International Sàrl Purified mesenchymal stem cell compositions
WO2011049291A3 (ko) * 2009-10-23 2011-07-21 가톨릭대학교 산학협력단 ＴＧＦβ를 코딩하는 뉴클레오티드 서열이 도입된 간엽줄기세포 및 그의 용도
US11708560B2 (en) 2010-10-08 2023-07-25 Mesoblast International Sarl Enhanced MSC preparations
US12410405B2 (en) 2010-10-08 2025-09-09 Mesoblast International Sàrl Enhanced MSC preparations
US10041039B2 (en) 2012-03-29 2018-08-07 Jcr Pharmaceuticals Co., Ltd. Method for producing pluripotent stem cells derived from dental pulp
WO2013146992A1 (ja) 2012-03-29 2013-10-03 日本ケミカルリサーチ株式会社 歯髄由来の多能性幹細胞の製造方法
AU2013370932B2 (en) * 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
WO2014100857A1 (en) * 2012-12-24 2014-07-03 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
CN105658069A (zh) * 2013-11-04 2016-06-08 贝克顿·迪金森公司 多潜能基质细胞(msc)群体的免疫调节潜力
CN106573017B (zh) * 2014-06-30 2021-06-11 泰根尼克斯独资有限公司 用于治疗脓毒症的间充质基质细胞
KR102213527B1 (ko) 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
WO2016001846A1 (en) * 2014-06-30 2016-01-07 Tigenix S.A.U. Mesenchymal stromal cells for treating sepsis
CN106573017A (zh) * 2014-06-30 2017-04-19 泰根尼克斯独资有限公司 用于治疗脓毒症的间充质基质细胞
KR20170021343A (ko) * 2014-06-30 2017-02-27 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
RU2715866C2 (ru) * 2014-06-30 2020-03-03 Тихеникс С.А.У. Мезенхимальные стромальные клетки для лечения синдрома сепсиса
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
US11273182B2 (en) 2016-03-14 2022-03-15 Takeda Pharmaceutical Company Limited Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
US10357518B2 (en) 2016-03-14 2019-07-23 Tigenix S.A.U. Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
US12213998B2 (en) 2016-03-14 2025-02-04 Takeda Pharmaceutical Company Limited Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease
US11174461B2 (en) 2016-03-16 2021-11-16 Cynata Therapeutics Limited Colony forming medium and use thereof
US12545889B2 (en) 2016-03-16 2026-02-10 Cynata Therapeutics Limited Colony forming medium and use thereof
US12473547B2 (en) 2017-11-22 2025-11-18 Mesoblast International Sàrl Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer
RU2828728C2 (ru) * 2019-03-12 2024-10-17 Бёрингер Ингельхайм Вэтэринари Мэдсин Белджиум Иммуномодулирующие мезенхимальные стволовые клетки
WO2020182935A1 (en) * 2019-03-12 2020-09-17 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
EP4137141A4 (en) * 2020-04-13 2024-04-24 National University Corporation Tokai National Higher Education and Research System AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN THE KIDNEY
US20230137723A1 (en) * 2021-11-01 2023-05-04 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
EP4426322A4 (en) * 2021-11-01 2025-12-31 Mam Holdings Of West Florida L L C Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders

Also Published As

Publication number Publication date
EP2298861A3 (en) 2011-11-30
EP2298862B1 (en) 2017-08-30
US10960025B2 (en) 2021-03-30
EP2824175B2 (en) 2020-10-28
US20150017132A1 (en) 2015-01-15
US20050239897A1 (en) 2005-10-27
US20110318314A1 (en) 2011-12-29
US20110318315A1 (en) 2011-12-29
US9943547B2 (en) 2018-04-17
EP2824175A2 (en) 2015-01-14
US20100172885A1 (en) 2010-07-08
JP2010505764A (ja) 2010-02-25
EP2298863A3 (en) 2011-04-13
EP2298863A2 (en) 2011-03-23
US9694035B2 (en) 2017-07-04
US20140328807A1 (en) 2014-11-06
EP2298862A2 (en) 2011-03-23
EP2298864A3 (en) 2011-11-23
US10716814B2 (en) 2020-07-21
AU2005227295A1 (en) 2005-10-06
EP2298861B1 (en) 2017-09-13
US10828334B1 (en) 2020-11-10
AU2009200019A1 (en) 2009-02-05
US20140161776A1 (en) 2014-06-12
EP2298864B1 (en) 2017-10-11
EP1727892A1 (en) 2006-12-06
EP2824174B1 (en) 2018-11-28
EP2243826A2 (en) 2010-10-27
US20090180997A1 (en) 2009-07-16
WO2008042174A2 (en) 2008-04-10
US10729727B2 (en) 2020-08-04
EP2824175A3 (en) 2015-05-06
US20110142807A1 (en) 2011-06-16
EP1727892A4 (en) 2007-08-22
KR20090065478A (ko) 2009-06-22
EP1974016A2 (en) 2008-10-01
US20080213227A1 (en) 2008-09-04
EP1727892B1 (en) 2012-05-02
US20140154276A1 (en) 2014-06-05
EP2298861A2 (en) 2011-03-23
AU2010200916A1 (en) 2010-04-01
US20110311496A1 (en) 2011-12-22
CN101384702A (zh) 2009-03-11
US20200360442A1 (en) 2020-11-19
CA2564679A1 (en) 2005-10-06
EP2298862A3 (en) 2011-08-24
EP2243826A3 (en) 2013-11-06
JP2007530543A (ja) 2007-11-01
US20190175657A1 (en) 2019-06-13
EP2298863B1 (en) 2015-07-22
EP2824175B1 (en) 2017-11-29
EP1974016A4 (en) 2009-04-01
EP2824174A1 (en) 2015-01-14
EP2298864A2 (en) 2011-03-23
US20190240259A1 (en) 2019-08-08
US20110027238A1 (en) 2011-02-03
US11389484B2 (en) 2022-07-19
US20190201447A1 (en) 2019-07-04
CA2564679C (en) 2015-06-23
US20200246387A1 (en) 2020-08-06
AU2009200019B2 (en) 2012-08-02
EP3461884A1 (en) 2019-04-03
US20150272997A1 (en) 2015-10-01
US10668101B2 (en) 2020-06-02
US20090208463A1 (en) 2009-08-20
EP3461884B1 (en) 2025-05-28
CA2659825A1 (en) 2008-04-12
US20230076630A1 (en) 2023-03-09
WO2008042174A3 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
EP2824174B1 (en) Mesenchymal stem cells and uses therefor
CA2868733A1 (en) Mesenchymal stem cells for treating inflammation
AU2012205269B2 (en) Mesenchymal stem cells and uses therefor
AU2020201636B2 (en) Mesenchymal stem cells and uses therefor
HK1262056A1 (en) Mesenchymal stem cells and uses therefor
HK1205531B (en) Mesenchymal stem cells and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2564679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007505005

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005725577

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005227295

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005227295

Country of ref document: AU

Date of ref document: 20050315

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005227295

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005725577

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)